Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626439 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants
A Phase 1 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05626439 is a Phase 1 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 21 participants.
The verdict
NCT05626439, a Phase 1 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the relative bioavailability of alprazolam in plasma following a single dose of Staccato alprazolam compared to a single dose of oral alprazolam under fasted conditions
Interventions
- DRUG Staccato alprazolam
- DRUG Oral alprazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-12-28 |
| Est. Completion | 2023-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05626439
The ClinicalTrials.gov registry entry for NCT05626439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Staccato alprazolam is the first listed.
NCT05626439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05626439 about?
NCT05626439 is a clinical study titled "A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants". The purpose of the study is to evaluate the relative bioavailability of alprazolam in plasma following a single dose of Staccato alprazolam compared to a single dose of oral alprazolam under fasted conditions
What is the current status of trial NCT05626439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-12-28. Estimated completion is 2023-02-24.
What interventions are being tested in trial NCT05626439?
The interventions under investigation include: Staccato alprazolam (DRUG), Oral alprazolam (DRUG).
Who is sponsoring clinical trial NCT05626439?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.